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Abstract 
In diabetic retinopathy (DR), macular involvement can present as either macular edema or ischemia. Fluorescein angi-
ography remains the gold standard in the evaluation of retinal vascular perfusion and diagnosis of macular ischemia. 
However, it is a costly, time-consuming technique, it requires venipuncture, and reports of anaphylaxis and death 
related to fluorescein injections have been documented, despite their rarity. Optical coherence tomography (OCT) 
provides a fast and non-invasive method to assess retinal structures at a microscopic level. OCT angiography per-
mits the noninvasive study of retinal and choroid circulation via motion contrast imaging. Split-spectrum amplitude 
decorrelation angiography combined with OCT angiography has furthered the understanding of retinal and choroi-
dal vascular diseases, allowing the evaluation of retinal microvasculature and identification of subsequent disorders, 
including DR. Previous studies using OCT angiography have demonstrated that it may demonstrate DR findings such 
as microaneurysms, arteriolar wall staining, retinal neovascularization, and intraretinal microvascular abnormalities. 
The purpose of this article is to describe and discuss different concepts regarding OCT angiography, as well as its role 
in the diagnosis of DR and maculopathy.
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Background
Approximately 347 million people worldwide have diabe-
tes mellitus (DM) [1]. The worldwide prevalence of DM 
is predicted to grow to 430 million patients by 2030 [2]. 
Diabetic retinopathy (DR), a diabetic microangiopathy, is 
characterized by microaneurysms (MAs), capillary non-
perfusion, and ischemia within the retina [3–6]. It may 
cause several complications, such as diabetic macular 
edema (DME) and diabetic macular ischemia (DMI) [1, 
7–11]. In particular, capillary nonperfusion impairs the 
nutrition of the neuroglial tissues in the retinal paren-
chyma, and the resultant hypoxia increases the expres-
sion of vascular endothelial growth factor (VEGF), 
which promotes both angiogenic responses and vascular 
permeability [12]. Diabetic maculopathy is caused by a 
combination of both VEGF-mediated factors and inflam-
matory mediators [13–15].
DME occurs when high glucose levels cause capil-
laropathy that damages the blood supply to the retina. 
A hallmark of this disease is alterations in the blood-
retinal barrier that is characterized by pericyte loss and 
endothelial cell–cell junction breakdown [16]. Numerous 
treatments have been established to manage DME, such 
as focal or grid photocoagulation and antiangiogenic 
therapy, which have been recently shown to yield good 
results in the treatment of DME [7, 11, 17].
Fluorescein angiography is broadly recognized as an 
important tool in the diagnosis and treatment of DR 
[15]. However, it requires venipuncture, and reports of 
anaphylaxis and death related to contrast injections, 
although rare, have been documented [18]. In addition, 
the technique is costly and time-consuming, requiring 
up to 10 min for framing acquisition [19–21]. Neverthe-
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The development of optical coherence tomography 
(OCT) has revolutionized ophthalmology and provides a 
rapid and noninvasive method to assess retinal structures 
at the microscopic level [20]. Spectral domain OCT (SD 
OCT) has become an important tool with which to man-
age patients with DR [17].
OCT angiography permits the noninvasive imaging 
of retinal and choroidal circulation via motion contrast 
imaging [21, 22]. This relatively novel imaging technique 
obtains high-resolution volumetric blood flow informa-
tion and generates angiographic images in a matter of 
seconds [5, 6, 21, 22]. OCT angiograms are resampled 
with OCT B-scans from the same area, simultaneously 
allowing the assessment of structure and blood flow [21, 
23].
The high speed of SD OCT compared with ime-
domain OCT (TD OCT) has made the imaging of both 
the structure and blood flow possible [24, 25]. Several 
OCT-derived techniques have been successfully devel-
oped to image in vivo human eye microcirculation, such 
as phase-variance OCT (PV OCT), phase contrast OCT 
(PC OCT), and split-spectrum amplitude decorrelation 
angiography (SSADA), which will be discussed herein 
[24–26].
The purpose of this article is to describe and discuss 
different concepts regarding OCT angiography, as well as 
its role in the diagnosis of DR and maculopathy.
OCT angiography: technology applied to retinal 
disorders
Since it was first described to capture ophthalmic images 
in 1991, OCT has increasingly been used in clinical prac-
tice and ophthalmic research [27]. OCT angiography is 
a further step in OCT technology that allows microvas-
cular assessment by detecting blood flow. Different OCT 
angiography platforms and segmentation algorithms 
have been described, with the AngioVue software of 
RTVue XR Avanti (Optovue, Fremont, CA) being the first 
commercially available OCT angiography system [21, 22, 
24]. This device obtains volumetric scans of 304 ×  304 
A-scans at 70,000 A-scans per second in approximately 
3.0 s. The 3 × 3-mm OCT angiograms appear to provide 
higher resolution images than the currently available 
imaging techniques [20]. SSADA aims to improve the 
signal to noise ratio (SNR) [22, 24, 28, 29]. Its application 
with OCT angiography instrumentation has furthered 
the understanding of retinal and choroidal vascular 
diseases.
Using SSADA, Spaide and co-workers demonstrated 
in  vivo a distinct superficial capillary plexus (SCP) and 
deep capillary plexus (DCP), the latter of which includes 
the intermediate plexus [28, 30]. Thus, OCT angiography 
could be used to enrich the understanding of ischemic 
conditions that may affect the different layers of reti-
nal microcirculation, such as cotton wool spots, acute 
macular neuroretinopathy (AMN), paracentral acute 
middle maculopathy (DCP ischemia), and macular telan-
giectasia (MacTel) type 2 [28, 31–33]. Reports applying 
swept-source OCT technology (SS OCT) in patients with 
MacTel 2 have already shown structural abnormalities in 
the inner retina, such as retinal cavitation with draping of 
the internal limiting membrane and abnormalities in the 
outer retina, including disruptions of the photoreceptor 
ellipsoid segment that were not previously appreciated by 
fluorescein angiography [33].
The AngioPlex OCT angiography instrument (Carl 
Zeiss Meditec, Dublin, CA) improved the CIRRUS 
HD OCT scanning rate to 68,000 A-scans per second 
and introduced a tracking software known as Fast-
Trac retinal-tracking technology. The standard scan-
ning patterns available include 3  ×  3 and 6  ×  6  mm 
OCT angiograms. The angiographic images are gen-
erated using a complex algorithm that analyzes differ-
ences in both the intensity and phase information from 
repeated B-scans in the same position. This process is 
repeated at multiple adjacent positions to generate an 
en face flow volume. This algorithm is known as OCT 
microangiography-complex (OMAG) [34]. AngioPlex 
and AngioVue have been compared in clinical prac-
tice, and it was demonstrated that AngioPlex requires 
a shorter time and provides a higher number of images 
available for analysis with fewer motion artifacts [35]. 
Another SD OCT angiography device is the NIDEK 
RS-3000 (NIDEK, Aichi, Japan), which provides scans 
that range from 3 ×  3 to 9 ×  9 mm. Moreover, up to 
a 12  ×  9-mm panorama image can be automatically 
generated.
SS OCT technology uses longer wavelength infrared 
light (1050  nm) than conventional SD OCT. This tech-
nology enables improved penetration into tissue and 
imaging through optical opacities and is invisible to the 
subject. The DRI OCT (Triton SS OCT; Topcon, Tokyo, 
Japan) imaging systems, including the Atlantis  proto-
type technology, can acquire 100,000 A-scans per sec-
ond in both healthy and diseased eyes. The volumetric 
OCT scans can be acquired over a 3  ×  3-mm field of 
view in approximately 4  s of the total OCT scan time. 
Each B-scan position is repeatedly scanned 4 times. The 
examination field can be enlarged to 6 × 6 mm (Triton SS 
OCT and Atlantis) or even to 12 × 9 mm (Atlantis proto-
type only) [36]. The algorithm used is called OCTA Ratio 
Analysis (OCTARA). It is based on a ratio calculation in 
which the full spectrum is kept intact; therefore, the axial 
resolution is preserved. This method provides advantages 
over differentiation-based approaches while possessing 
improved sensitivity over methods based on amplitude 
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decorrelation [36]. Stanga et  al. studied diabetic macu-
lopathy and PDR with the Triton SS OCT platform. The 
authors concluded that it provides additional informa-
tion regarding the localization and morphology of NV 
in the optic disc (NVD) and in more than half of the NV 
elsewhere (NVE), suggesting that it is a noninferior tech-
nique to study posterior pole alterations compared with 
fluorescein angiography [37].
OCT angiography can assess retinal and choroidal 
microcirculation, identifying subsequent anatomical 
findings in many retinal diseases, including DR [5, 6, 15, 
25, 30, 32]. The technique allows the study of retinal deep 
plexi, while conventional fluorescein angiography only 
shows the superficial plexus. Thus, OCT angiography has 
been used to help diagnose DR-associated complications, 
but further reports are needed to expand our under-
standing of DR pathogenesis.
Diabetic retinopathy R and OCT angiography
Numerous clinical findings related to DR have been iden-
tified using OCT angiography [6, 20, 38, 39]. Structural 
OCT angiograms identified different lesions in singular 
stages of DR [6]. OCT angiography is not dependent on 
contrast injection, which helps to provide detailed infor-
mation regarding capillaries without fluorescein leakage 
[5, 20].
Ishibazawa et al. [6] concluded that OCT angiographic 
techniques could be used to study the origin of microa-
neurysms, describing them as demarcated saccular or 
fusiform shapes of focally dilated capillary vessels in the 
inner retina (Fig. 1). Despite this improved identification, 
reports have demonstrated that the number of microa-
neurysms was significantly lower than that obtained by 
conventional angiography but also that OCT angiogra-
phy had the added benefit of localizing these lesions to 
Fig. 1 Microaneurysm assessment using OCT angiography. This image was obtained from a diabetic patient and demonstrates microaneurysms. 
He was subjected to fluorescein angiography (a, b) and OCT angiography (c, d). Microaneurysm topography was compared using conventional 
angiography (b) and a 3 × 3-mm OCT angiogram obtained from SCP (d) (yellow arrows)
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their exact intraretinal depths [13, 39]. Miwa et al. [12], 
using OCT angiography, detected only 41.0 ±  16.1% of 
the microaneurysms identified in the fluorescein angiog-
raphy images. Using 6 × 6-mm OCT angiograms, some 
authors were unable to reliably identify microaneurysms, 
probably due to their relatively low flow and scan concen-
trations [5]. Another possible reason for this result may 
be the focal staining of the capillary walls or surround-
ing tissues in the microaneurysms that clearly identi-
fies them in the fluorescein angiography images, despite 
OCT angiography, because these factors are independent 
of erythrocyte movement [12].
Other DR clinical findings, such as arteriolar wall stain-
ing, neovascularization, and intraretinal microvascular 
abnormalities (IRMA), have divergent appearances on 
OCT angiography and fluorescein angiography. Wall 
staining and arteriolar narrowing have been illustrated as 
intense attenuation of microcirculation caliber on OCT 
angiography. IRMA, depicted as dilated terminal ves-
sels surrounded by capillary loss, were similarly identi-
fied with OCT angiography and fluorescein angiography 
(Fig. 2) [5]. OCT angiograms clearly visualized new ves-
sels on the disc (NVD) that persisted as spiral, looped, 
and irregular structures after initial anti-VEGF therapy 
[6]. Retinal NV is mostly detected by observing the flow 
signal above the internal limiting membrane. Hyperfluo-
rescent lesions on fluorescein angiography that appeared 
indistinguishable from an MA were identified as NV 
using OCT angiography. This information may help us 
to understand why some patients with PDR and vitre-
ous hemorrhage do not have a definitive NV on fluores-
cein angiography, as long as this method does not always 
identify all NV [5].
Diabetic macular ischemia on OCT angiography
Diabetic macular ischemia (DMI) is associated with 
functional retinal damage, and its diagnosis predicts 
DR progression [4, 19, 40, 41]. It is characterized by the 
enlargement and disruption of the foveal avascular zone 
(FAZ) and by retinal capillary loss in other noncontigu-
ous areas of the macula (capillary dropout) (Fig. 2) [41]. 
It has been postulated that the selective loss of pericytes 
and thickening of the basement membrane in retinal cap-
illaries occur due to the effects of chronic hyperglycemia, 
leading to capillary occlusion, one of the characteristics 
findings of DMI [14]. Sim et  al. [15, 40] demonstrated 
that approximately 41% of patients with DR in a tertiary 
hospital setting had some degree of macular ischemia. 
DMI is usually associated with reduced visual acuity (VA) 
in the eyes with moderate to severe grades of ischemia, 
but VA is preserved in milder grades of ischemia [10, 41, 
42].
Because antiangiogenic therapy has become one of the 
treatments of choice for managing DR, the diagnosis of 
DMI has become more important, especially because 
antiangiogenic therapy can obscure the clinical find-
ings related to ischemia progression [4, 19, 40, 41, 43]. 
Angiogenic factors, mainly VEGF, are believed to play a 
protective role in ischemic retinal disorders, improving 
volumetric blood flow and protecting retinal cells against 
apoptotic conditions [43]. Nevertheless, Campochiaro 
et  al. [44] concluded that monthly injections of ranibi-
zumab (Lucentis; Genentech, San Francisco, US) could 
diminish, but not completely prevent, retinal capillary 
closure in patients with DME.
Fluorescein angiography was introduced in 1961, and 
it has become the gold standard imaging modality for 
assessing the macular capillary network and its patholog-
ical conditions, such as macular ischemia [30, 43]. How-
ever, this method cannot distinguish between superficial 
and deep capillary plexi, as it displays in two-dimensional 
images the capillary bed of the superficial vascular plexus 
(Fig. 3) [20, 22, 30, 45].
Recent publications have shown that OCT angiography 
clearly depicts nonperfusion in DR [5, 6, 12, 20]. It pro-
vides an objective automated study of macular capillary 
nonperfusion as a potential sign of central ischemia [4]. 
Using OCT angiography with SSADA in healthy partic-
ipants (n =  105), Wang et  al. measured a mean FAZ of 
0.35 ± 0.12 mm2. In addition to DMI, a larger FAZ was 
found in subjects with shorter axial lengths, hyperopia, 
increased subfoveal choroidal thicknesses, thicker lenses, 
shallower anterior chamber depths, and other charac-
teristics [45]. Bradley et al. [15] demonstrated moderate 
agreement between the DMI grading results for OCT 
angiography (AngioVue platform) and fluorescein angi-
ography in 24 diabetic patients using standard ETDRS 
protocols.
Hwang et al. [5] studied patients with proliferative DR 
(PDR), identifying FAZ enlargement and irregularities, 
as well as areas of capillary dropout. Miwa et  al. [12] 
demonstrated that FAZ areas in OCT angiograms in the 
superficial layer were smaller than those in the fluores-
cein angiography images and were correlated with each 
other, agreeing with the finding that OCT angiography 
images often delineate the vascular structures in the 
nonperfused areas shown by fluorescein angiography. 
Usually, retinal microcirculation imaging is improved 
on OCT angiography despite fluorescein angiography 
(Fig. 4).
The identification of DCP by OCT angiography plays 
an important role in the setting of DMI (Fig. 5). Experi-
mental studies have shown that the DCP contributes 
to photoreceptor inner segment oxygen requirements 
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Fig. 2 Intraretinal microcirculation and capillary nonperfusion. This patient was diagnosed with PDR. Fundus photograph and fluorescein angiog-
raphy (a, b). Images of 3 × 3-mm fluorescein angiography (c) and OCT angiography were obtained (d). The white arrowheads indicate superficial 
collaterals with adjacent nonperfusion areas (orange arrowheads) (c). The corresponding SD OCT B-scan is also shown (e)
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(10–15%), particularly during dark adaptation [46]. 
Recently, some authors have postulated that patients with 
DCP nonperfusion had an outer retina disruption on SD 
OCT in DMI, corresponding to areas of capillary non-
perfusion at the level of the DCP [47, 48]. Yi et  al. [49] 
demonstrated that during systemic hypoxia, the inner 
retina contribution to the metabolic needs of the outer 
retina microcirculation become even more significant 
because the choroidal vasculature fails to autoregulate its 
blood supply in the hypoxic setting. Couturier et al. [13] 
concluded that SCP capillary rarefaction was better iden-
tified on OCT angiography. Nevertheless, the DCP non-
perfused areas were observed in only 35% of the subjects 
studied.
Recently, a novel quantitative graphic mapping tech-
nique for studying and displaying retinal vascular 
perfusion density using OCT angiography was devel-
oped. The authors applied software to images obtained 
from the Optovue SSADA algorithm that translates the 
OCT angiogram for each layer into qualitative and quan-
titative data using perfusion density analysis. Diabetic 
patients had significantly poorer capillary perfusion on 
SCP, DCP, and choriocapillaris than the controls in both 
the 3 × 3-mm and 6 × 6-mm settings. Subgroup analysis 
showed that normal subjects had higher capillary perfu-
sion rates than patients diagnosed with mild non-prolif-
erative DR (NPDR) (Fig. 6) [8].
General perspectives and critical improvements
Previously, the available OCT angiography devices were 
used to provide high-resolution OCT angiograms in 
patients with retinal diseases, including diabetic patients. 
Fig. 3 Improving retinal imaging in DR on OCT angiography. This fluorescein angiography image (a) is overlapped by a 3 × 3-mm OCT angiogram 
obtained from the SCP (b), displaying better details in the absence of dye staining and leakage
Fig. 4 Perifoveal perfusion density. Diabetic macular ischemia is demonstrated on fluorescein angiography (a) and a 3 × 3-mm OCT angiogram 
obtained from the SCP (b). Corresponding perfusion density mapping is represented by color-coded topographic maps with quantitative data (c)
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Most of them apply the motion contrast concept to 
generate volumetric blood flow information, providing 
angiographic images after comparing sequential B-scans. 
However, other techniques have been described to image 
retinal blood flow, such as SS OCT, PV OCT, and Dop-
pler OCT.
Doppler OCT has been used in conjunction with avail-
able SD OCT instrumentation. The Doppler effect is 
based on signals back-scattered from moving particles 
[24, 26, 50–52]. Doppler OCT is particularly useful for 
comparing depth scans, using this information to calcu-
late the flow component parallel to the imaging direc-
tion (called axial flow) [51, 53]. Nevertheless, without 
dedicated scanning protocols, this technique is limited 
to the detection of strictly slow flow [54]. Furthermore, 
the inherent disadvantage of the angle dependence of the 
Doppler phenomenon has prevented it from becoming a 
reliable clinical tool for imaging retinal blood flow [52].
PV OCT has been used to image retinal circulation 
by Fingler et al. and Kim et al. The method differs from 
Doppler OCT by generating increased SD OCT imaging 
speeds, maintaining the previously demonstrated ability 
to display fast and slow blood flow independent of imag-
ing orientation [51].
The SS OCT technique utilizes a 1050-nm wave-
length instead of the 800-nm wavelength used in most 
Fig. 5 Diabetic macular ischemia and OCT angiography. This patient was diagnosed with diabetic macular ischemia, represented by superficial 
capillary plexus (SCP) (a) and deep capillary plexus (DCP) (b) OCT angiography images. En face OCT angiograms from the SCP and DCP (c, d, respec-
tively) are also displayed
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commercially available SD OCT instruments [22, 33, 39, 
52]. There has been active research interest in exploring 
SS OCT systems at the 1-µm wavelength range for imag-
ing ocular posterior segments, offering the advantages 
of improved sensitivity roll-off and increased penetra-
tion depth into the choroidal tissue, higher resolution 
images, and a faster acquisition time than conventional 
SD OCT devices [52]. Thus, SS OCT angiography is a 
promising method that has numerous algorithms [33, 
52]. The Massachusetts Institute of Technology has 
developed an OCT angiography prototype using this 
technology with a faster acquisition rate than that of 
commercially available SS OCT angiography instru-
ments. This ultra-high-speed prototype employs a ver-
tical cavity surface emitting laser (VCSEL) operating at 
a 1060-nm wavelength that allows increased light pen-
etration into pigmented tissues and improved choroidal 
blood flow visualization compared with the light source 
used in SD OCT. This SS OCT angiography system 
obtains 500 × 500 A-scans at 400,000 A-scans per sec-
ond in approximately 3.8 s [22].
Some commercial OCT angiography manufacturers 
are starting to include automated algorithms for map-
ping capillary density in their instrument software [8, 22]. 
Because OCT angiography imaging is based on motion 
contrast, it is properly suited for assessing macula perfu-
sion status, such as identifying regions with no detectable 
flow [8]. The follow-up image capture and intersession 
repeatability of automated vessel density measurements 
have been objectively demonstrated in healthy individu-
als. Further reports are needed in diabetic patients [55, 
56]. In addition to mapping capillary perfusion, novel 
methods that allow the assessment of relative blood flow 
speeds have been developed. Variable interscan time 
analysis (VISTA), an OCT angiography imaging and 
analysis technique, was developed to overcome the limi-
tation that typical OCT angiography does not directly 
measure blood flow speeds. Ploner et al. [57] concluded 
that abnormal flow speed was detected in several macu-
lar disorders, including DR.
OCT angiography must be properly compared with flu-
orescein angiography, as long as both methods have some 
limitations. OCT angiography requires that the patient 
fixate precisely for several seconds, whereas a useful fluo-
rescein angiographic frame can be obtained in a fraction 
of a second [30]. In its current state, most commercially 
available OCT angiography systems suffer from motion 
artifacts and a relatively small field of view, which can be 
improved with further development efforts [4–6, 20, 25]. 
This instrument uses image alignment based on scanning 
laser ophthalmoscope (SLO) images obtained immedi-
ately prior to image capture. This eliminates the relatively 
Fig. 6 Ischemic DME. Fluorescein angiography (a) compared with 
the 3 × 3-mm SCP OCT angiogram (b). DCP (c) and corresponding 
SD OCT B-scan (d)
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long image acquisition time necessary for image capture 
when the automatic tracking function is used [56].
Conclusions
OCT angiography is a relatively new and promising imag-
ing technique that uses SD OCT or SS OCT for the 3D visu-
alization of the retinal and choroidal microcirculation without 
the need for dye injection. While fluorescein angiography is 
still considered the gold standard for imaging retinal vascula-
ture in vivo, OCT angiography is a non-invasive, relatively fast 
imaging study that can be performed alongside routine OCT 
imaging. Several studies have demonstrated its applicability 
in diabetic patients, such as providing a prognosis and assess-
ing treatment effects. Presently, OCT angiography allows the 
study of the retinal vascular bed and discriminates between 
superficial and deep retinal vascular plexi, which cannot be 
portrayed by conventional fluorescein angiography. In contrast, 
fluorescein angiography techniques are still superior in identi-
fying slow blood flow structures such as microaneurysms. In 
summary, OCT angiography may provide images with greater 
detail regarding macular status and may become a novel imag-
ing technique for the diagnosis of DMI in conjunction with 
fluorescein angiography in the management of DR.
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